MAP2K7 and glioblastoma: Focusing on the most clinically advanced MEK inhibitor, trametinib, we demonstrated low-level synergistic activity upon FAK-WT GBM cell survival and invasion endpoints when combined with multiple small-molecule FAK inhibitors.